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Introduction: Detection of epidermal growth factor receptor (EGFR) 
mutation has become the most critical molecular test in managing 
patients with advanced lung adenocarcinoma. Whether patients with 
discrepant EGFR mutation results determined by low- and high-sen-
sitivity methods have different clinical outcomes with EGFR tyrosine 
kinase inhibitor (TKI) treatment needs to be further evaluated.
Methods: Genomic DNA from serial lung adenocarcinoma samples 
that were EGFR wild-type determined by direct sequencing (DS) 
were reanalyzed using Scorpion/Amplification Refractory Mutation 
System (ARMS). The outcomes with EGFR-TKI treatment among 
patients with discrepant EGFR mutation results between DS and 
Scorpion/ARMS versus patients with EGFR mutations detected by 
DS were studied.
Results: Of the 130 tumors studied, 28 (21.5%) were found to have 
EGFR mutations by Scorpion/ARMS. Discrepant EGFR mutation 
testing results were more common in samples from nonsmokers 
than in samples from smokers (30.7% versus 9.1%; p = 0.003) and 
in pleural than in nonpleural samples (62.5% versus 18.9%; p = 
0.012). There was no significant difference in the abundance of 
cancer cells in region(s) selected for testing (26.2% in tumor cell 
percentage ≤50 versus 16.9% in tumor cell percentage >50; p = 
0.201). During EGFR-TKI treatment, the progression-free survival 
in patients with discrepant EGFR mutation results was similar to 
those with EGFR mutations detected by DS (median, 13.4 versus 
10.9 months; p = 0.225).
Conclusions: DS overlooked EGFR mutation in a significant number 
of lung adenocarcinoma patients. These patients could have obtained 
the same benefit from EGFR-TKI when a high-sensitivity method 
such as Scorpion/ARMS was applied.
Key Words: Lung adenocarcinoma, Epidermal growth factor recep-
tor, Mutation, Tyrosine kinase inhibitor.
(J Thorac Oncol. 2014;9: 91–96)
Epidermal growth factor receptor (EGFR), a transmem-brane receptor tyrosine kinase, is frequently overexpressed 
or dysregulated in a variety of malignancies.1 EGFR tyrosine 
kinase inhibitor (TKI) was developed as an anticancer therapy 
by blocking the overactive EGFR signaling in cancer cells. 
Although the clinical efficacy was not impressive in the early 
clinical trials, some “super-responders” were observed in lung 
adenocarcinomas. Because of two landmark studies,2,3 it is 
clear that specific somatic mutations at the EGFR tyrosine 
kinase domain are the key determinants for the effectiveness 
of EGFR-TKI. Today, it is well accepted that EGFR muta-
tion is the driving force of some lung adenocarcinomas, and 
EGFR-TKI can very effectively kill these tumors by hitting 
their Achilles’ heel.4 In fact, several large randomized trials 
have consistently shown that, in terms of progression-free 
survival (PFS), EGFR-TKI is superior to conventional che-
motherapy in treatment-naïve EGFR-mutant lung adenocar-
cinoma patients.5–8
Sanger direct sequencing (DS) is the classic method 
to detect gene mutations and is considered the current stan-
dard method. DS can detect both known and novel mutations; 
however, its detection sensitivity is low and at least 25% of 
the sample needs to be mutant DNA.9 Its low detection sen-
sitivity is not an issue in basic research but may cause sig-
nificant deficiency in clinical practice. On one hand, there 
are not only EGFR-mutant cancer cells but also a lot of 
EGFR-wild-type (EGFR-WT) stromal cells in tumors. On the 
other hand, emerging evidence suggested that not all tumor 
cells harbor (the same) EGFR mutation in an EGFR-mutant 
tumor.10,11 Consequently, some clinical samples may give rise 
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to a false-negative testing result by DS and this phenomenon 
may partly explain the high response rate of EGFR-TKI in 
EGFR-WT patients in previously reported clinical series 
including ours.12
In the past few years, several methods have been devel-
oped to improve the detection sensitivity of EGFR mutations.9 
One strategy is to use the mutant allele-specific polymerase 
chain reaction (PCR) combined with the real-time detec-
tion technology, such as Scorpion/Amplification Refractory 
Mutation System (ARMS), which can lower the detection limit 
down to 1% mutant DNA present in the sample. Therefore, 
certain abundance of EGFR-mutant DNA may result in dis-
crepant results determined by low- and high- sensitivity 
mutation detection methods. Whether the discrepant EGFR 
mutation results will contribute to different EGFR-TKI treat-
ment outcomes in clinical patients is still controversial.13,14 In 
this study, by using high-sensitivity Scorpion/ARMS method, 
we reanalyzed the EGFR mutation status in serial lung ade-
nocarcinoma samples which were found to have no EGFR 
mutations by DS method. Both the patient and tumor charac-
teristics were evaluated and the patients’ clinical outcome to 
EGFR-TKI treatment was compared with those of a control 
group whose tumors were found to have EGFR mutations by 
DS method.
PATIENTS AND METHODS
Patients
The database at the Department of Pathology and 
Laboratory Medicine in Taipei Veterans General Hospital 
was used to retrieve tumors that were diagnosed with lung 
adenocarcinoma and had been tested for EGFR mutation by 
DS method from a period of 2008 to 2010. Among tumors 
diagnosed as EGFR-WT, we further identified cases with 
adequate remaining DNA (of the same batch for DS method) 
to submit for EGFR mutation testing by Scorpion/ARMS 
method. Patients whose tumors were found to have the sensi-
tive EGFR mutations (exon 19 deletion, L858R, G719X, and 
L861Q) by DS method in the same time period were selected 
as the positive control group. Patients with other EGFR muta-
tions were excluded because the function of those mutations 
is either EGFR-TKI-resisting or not clear. Patients’ clini-
cal characteristics and EGFR-TKI treatment outcomes were 
reviewed through the electronic chart record and serial chest 
computed tomography imaging. This study was approved by 
the Committee of Pathology Specimens and the Institution 
Review Board of Taipei Veterans General Hospital.
Tumor Samples
Formalin-fixed, paraffin-embedded tissue sections were 
used for EGFR mutation testing. One of the consecutive sec-
tions was stained with hematoxylin and eosin and reviewed 
by pathologists to select tumor region(s) for genomic DNA 
extraction. The percentage of cancer cells in the selected 
region(s) was assessed in a 10% increment by two indepen-
dent pathologists. The selected tumor region(s) was marked 
on deparaffined tissue sections, manually microdissected, and 
followed by genomic DNA extraction using PicoPure DNA 
extraction kit (Arcturus/Applied Biosystems, Foster City, 
CA). The extracted DNA was evaluated and quantified by 
Nanodrop 2000 (Thermo Fisher Scientific, Waltham, MA).
EGFR Mutation Detection by DS Method
Exons 18, 19, 20, and 21 of the EGFR gene were ampli-
fied as previously described12 with minor modification, namely, 
nested PCR was only performed on specimens when their first 
PCR products could not be visualized on 2% agarose gel elec-
trophoresis. The first PCR was carried out in a volume of 25 μl 
containing 2 μl of DNA, ×1 Taq Master Mix Red (Ampliqon 
III, Odense, Denmark), and 0.5 μM of each primer. The PCR 
reaction was carried out for 35 cycles at 95°C for 40 seconds, 
at 56°C for 40 seconds, and at 72°C for 40 seconds, followed 
by 5 minutes extension at 72°C. For the nested PCR, the DNA 
amplification was performed with the same PCR reaction 
program by using 2 μl of first PCR products as template, ×1 
Taq Master Mix Red, and 0.5 μM of each of primers. Sanger’s 
sequencing was performed with forward or reverse prim-
ers, and the sequence analysis was carried out by Mutation 
Surveyor software (SoftGenetics, State College, PA).
EGFR Mutation Detection by High-Sensitivity  
Scorpion/ARMS Method
The remaining DNA after DS analysis was subjected to 
high-sensitivity EGFR mutation analysis using EGFR RGQ 
PCR kit (Qiagen, Manchester, United Kingdom) on a Rotor-
gene platform. The kit contained primers designed for detec-
tion of 29 common EGFR mutations (L858R, L861Q, S768I, 
T790M, 3 G719 missense mutations, 19 deletions in exon 
19, and 3 insertions in exon 20) based on ARMS PCR and 
Scorpion detection technology. Analysis was carried out as 
described in the operation instruction of the kit.
Statistical Analyses
The association between patients and tumor character-
istics was analyzed by the χ2 test and the Fisher’s exact test. 
EGFR-TKI treatment response among different groups was 
compared by nonparametric test. Survival curves were plotted 
by the Kaplan–Meier method and compared by log-rank test. 
When multiple comparisons were performed, the cutoff level 
of α error was reduced using Bonferroni correction. Analyses 
and figures were carried out with PASW Statistics 18.0 (SPSS 
Inc., Chicago, IL).
RESULTS
Patient Characteristics and Tumor 
EGFR Mutation Status
From December 2008 to September 2011, a total of 
851 samples were received for EGFR mutation testing by DS 
method and 471 (55.3%) of them were positive for mutation. 
Among those without EGFR mutations, 137 consecutive sam-
ples that fulfilled the inclusion criteria of this study were iden-
tified. Seven samples were excluded for further analysis: five 
were not primary lung cancer and two were cell block materi-
als. Among these 130 primary lung adenocarcinoma tumors 
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that were regarded as EGFR-WT by DS method, 28 were 
found to have EGFR mutations by Scorpion/ARMS method. 
Taking the high-sensitivity method as the standard, the false-
negative rate of DS method to detect sensitive EGFR muta-
tions was 21.5% (95% confidence interval, 14.4%–28.7%). 
Patient characteristics are summarized in Table 1. Discrepant 
EGFR mutation results were more common in samples from 
nonsmokers than in samples from smokers (30.7% versus 
9.1%; p = 0.003). There was no difference in age and sex.
The Roles of Nested PCR and Tumor Cell  
Percentage on the Discrepant EGFR Mutation  
Results
Due to the limited amount of available tumor tissue, 
nested PCR was performed in most specimens (108 of 130, 
83.1%) to make enough PCR products for DS. Most dis-
crepant EGFR mutation results occurred in samples which 
needed nested PCR (27 of 108) and only one happened in 
those which made enough products by simple PCR (1 of 
22; p = 0.044).
The distribution of the tumor cell percentage in each 
sample is shown in Figure 1. There was no significant asso-
ciation between the tumor cell percentage and discrepant 
EGFR mutation results (p = 0.102). In a further analysis, the 
false-negative rates of EGFR mutation testing by DS method 
were not significantly different in samples with tumor cell per-
centage either 50% or less or more than 50% (26.2% versus 
16.9%; p = 0.201).
The Roles of Tissue Types on the 
Discrepant EGFR Mutation Results
The most common type of specimens sent for EGFR 
mutation analysis was lung tissue (n = 104), followed by 
lymph nodes (n = 14), pleura (n = 8), and others (n = 4). 
Interestingly, the false-negative rates of EGFR mutation test-
ing by DS method were significantly higher in pleural than 
nonpleural samples (62.5% versus 18.9%; p = 0.012). Among 
the eight pleural samples, seven were obtained by percutane-
ous biopsy and one was through video-assisted thoracoscopy. 
In seven percutaneous biopsied samples, four were indeed 
EGFR-mutant tumors but missed by DS method. The tumor 
cell percentages in these samples were 60%, 50%, 40%, 
and 10%, respectively. DS method also failed to identify the 
EGFR mutation in the thoracoscopic biopsied sample which 
contained 10% tumor cells.
Survival in Patients with Discrepant 
EGFR Mutation Testing Results
Eighty-five of the 130 patients in our cohort had 
received single-agent EGFR-TKI treatment; 64 (group A) 
had EGFR-WT tumors defined by both mutation detec-
tion methods, and 21 (group B) had tumors with EGFR 
mutations which were detected by Scorpion/ARMS but not 
DS method. A positive control group (group C) from the 
same time period was established, consisting of 58 lung 
adenocarcinoma patients who had sensitive EGFR muta-
tions detected by DS method and had been treated with 
EGFR-TKI. Patient and tumor characteristics are summa-
rized in Table 2.
During EGFR-TKI treatment, patients with concordant 
testing results of EGFR-WT tumors had a shorter PFS than 
those with EGFR-mutant tumors defined by either Scorpion/
ARMS or DS method (median PFS = 1.8, 13.4, and 10.9 
months, respectively; p < 0.001; Fig. 2). The overall survival 
(OS) was also significantly different among these patients 
(median OS = 18.2, 37.6 and 27.5 months, respectively; 
p = 0.001). Interestingly, there was no difference in both PFS 
and OS among the patients with EGFR-mutant tumors no 
matter they were diagnosed by low-sensitivity DS method or 
high-sensitivity Scorpion/ARMS method alone (p = 0.225 
and 0.594, respectively).
TABLE 1.  Patient and Tumor Characteristics
Concordant  
gr. DS: Wild-Type 
S/A: Wild-Type  
(n = 102)
Discrepant  
gr. DS: Wild-Type 
S/A: Mutant  
(n = 28) p
Age 0.284
  Median (range) 63 (30–91) 68 (44–86)
Sex 0.201
  Male 68 15
  Female 34 13
Smoking history 0.003
  Never 52 23
  Ever 50 5
Type of specimen 0.033
  Lung 83 21
  Pleura 3 5
  Lymph node 12 2
  Others 4 0
Method to obtain specimen 0.071
  Bronchoscopic biopsy 29 3
  Percutaneous needle 
biopsy
46 19
  Surgical biopsy/resection 27 6
Tumor cell percentage in 
specimen (%)
0.201
  ≤50 48 17
  >50 54 11
Nested PCR 0.044
  No 21 1
  Yes 81 27
EGFR mutation status N.A.
  Wild-type 102 0
  Exon 19 deletion 0 12
  L858R 0 13
  Exon 19 deletion and 
L858R
0 2
  L861Q 0 1
DS, direct sequencing; S/A, Scorpion/Amplification Refractory Mutation System 
method; PCR, polymerase chain reaction; EGFR, epidermal growth factor receptor; 
N.A., not applicable.
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EGFR-TKI Treatment Response in 
Patients Categorized by Different 
EGFR Mutation Testing Methods
According to the definition used in Response Evaluation 
Criteria in Solid Tumors criteria, 41, 19, and 55 patients had 
measurable disease in groups A, B, and C, respectively. The 
objective response rate was significantly higher in patients 
with EGFR-mutant tumors (groups B and C combined) than 
those with EGFR-WT tumors (group A) (70.3% versus 9.8%; 
p < 0.001). However, there was no difference between patients 
whose tumor EGFR mutation status was analyzed using 
Scorpion/ARMS (group B) or DS (group C) method (73.7% 
versus 69.1%; p = 0.706).
DISCUSSION
In this study, in a high EGFR mutation prevalence area, 
we showed that Scorpion/ARMS method could identify sen-
sitive EGFR mutations in up to 22% of lung adenocarcino-
mas which were considered EGFR-WT by DS method. We 
also demonstrated that patients with EGFR mutations missed 
by DS had similar response rate and survival to those with 
mutations detected by DS. These findings highlight the major 
limitation of DS for EGFR mutation detection in current clin-
ical practice. It has been clear that EGFR-TKI can provide 
better treatment outcome and quality of life than cytotoxic 
chemotherapy as the front-line therapy in patients with EGFR-
mutant non–small-cell lung cancer. Therefore, using DS as the 
primary strategy for EGFR mutation detection could signifi-
cantly compromise patients’ prognosis because it may mis-
place one in every five DS-defined “EGFR-WT” patients into 
inappropriate treatment.
The failure rate of EGFR mutation detection by DS 
method in our study was similar to a few previous reports15,16 
but higher than the others.17,18 We consider it is reasonable 
because the negative predictive value of a test should be 
closely related to the prevalence of the disease in a given 
population. Therefore, it was not surprising that EGFR muta-
tion detection failure rates by a low-sensitivity method were 
higher in East-Asian studies,15,16 including ours, than those 
with Caucasian-predominant population.17,18 It also explained 
our observation that discrepant EGFR mutation results by 
low- and high-sensitivity methods were more common in non-
smokers than smokers because EGFR mutations were more 
frequent in nonsmoker lung adenocarcinomas.19
Low percentage of tumor cells in clinical samples was 
generally considered the reason for the false-negative result of 
EGFR mutation by DS, and most recommendations suggested 
that the tumor cell percentage should be at least 50%.20–22 
However, when we vigorously examined the tumor cell per-
centage of each sample in this study, we could not find a corre-
lation. We therefore speculated that the percentage of mutant 
DNA, but not tumor cell per se, was the decisive factor for the 
sensitivity of mutation detection.9 It is well documented that 
EGFR gene amplification is a frequent event in EGFR-mutant 
tumors. In addition, more complicatedly, an EGFR-mutant 
tumor may actually consist of not only EGFR-mutant but also 
EGFR-WT tumor cells.10,11 Therefore, the summation of the 
percentage of tumor cells in a given sample, the proportion of 
EGFR-mutant versus EGFR-WT tumor cells, and EGFR gene 
amplification status in EGFR-mutant tumor cells will contrib-
ute to the final ratio of mutant-to-WT DNA and then the result 
of EGFR mutation detection by DS method.
In addition to the mutant DNA percentage in raw 
samples, types of PCR reaction (simple or nested PCR) 
will also play a role in the final result of Sanger sequencing. 
Theoretically, in a sample with a fixed mutant-to-WT DNA 
ratio, the final mutant-to-WT signals detected by DS will be 
amplified with the increasing cycles of PCR reaction. Because 
of limited amount of DNA obtained from clinical samples, 
nested PCR was routinely performed before DS in our ear-
lier study.12 Along with the improvement of the personnel and 
technique, nested PCR has been carried out only when the 
first PCR products could not be visualized on agarose gels. 
As expected, although nested PCR still had to be executed for 
most specimens (83.1%), avoidance of the second PCR sig-
nificantly reduced the false-negative rate of EGFR mutation 
detection by DS method.
Interestingly, we found that tissue type may also be 
a factor contributing to the EGFR mutation testing results 
by DS method. The false-negative rate was extraordinarily 
high in pleural specimens (62.5%). The exact mecha-
nism was not clear. Both the tumor cell percentage and 
FIGURE 1.  Distribution of the proportion of tumor 
cells in the tumor region(s) selected for EGFR muta-
tion testing. Open bars represent samples which 
were EGFR-WT by both DS and Scorpion/ARMS and 
closed bars represent samples which had discrep-
ant EGFR mutation results, that is, EGFR-WT by DS 
but EGFR-mutant by Scorpion/ARMS. DS, direct 
sequencing; WT, wild-type; ARMS, Amplification 
Refractory Mutation System; EGFR, epidermal 
growth factor receptor.
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the necessity of nested PCR did not differ significantly in 
pleural versus nonpleural tissues. One of the possible rea-
sons was that tumor cell percentage in pleural samples was 
indeed significantly low but was overestimated because of 
the difficulty in differentiating between adenocarcinoma 
cells and reactive mesothelial cells by hematoxylin and 
eosin staining.23 Another plausible explanation was that 
reactive mesothelial cells might have EGFR gene amplifi-
cation, which has not yet been explored. Finally, and maybe 
most likely, it could simply be a biased conclusion caused 
by a small sample size (n = 8).
Predictably, patients with EGFR-mutant tumors 
have better response and longer survival than those with 
EGFR-WT tumors when they receive EGFR-TKI treatment. 
However, in contrast to a previous study by Zhou et al.,13 
we did not find significant differences in objective response 
rate and PFS in patients with tumors bearing EGFR muta-
tions detected by DS method or only by high-sensitivity 
Scorpion/ARMS method. There were several differences in 
terms of methodology between Zhou’s study and ours. First, 
they included patients with not only adenocarcinoma but 
also other non–small-cell types. Second, all their patients 
received gefitinib, but our patients received gefitinib and 
erlotinib at about equal frequency. Third, they only included 
patients with tumor samples which consisted of more than 
50% tumor cells. In our study, about 60% of the samples 
had tumor cells less than 50%. Although they had excluded 
samples with lower tumor cell percentage, the false-negative 
rate of EGFR mutation by DS method in their series was 
similar to ours (26.1% and 21.5%, respectively). This finding 
concurs with our conclusion that tumor cell percentage itself 
does not have significant impact on EGFR mutation testing 
by DS method.
There are several limitations in this study. First of 
all, it was a retrospective study; therefore, the clinical data 
were not perfectly collected. Second, we were not able to 
evaluate the EGFR gene copy number which in combina-
tion with tumor cell percentage could give a better esti-
mation of the mutant DNA amount. However, because 
EGFR-mutant tumors may also have WT EGFR allele, we 
have to develop a method which can differentially detect 
WT and mutant EGFR gene copy numbers. Third, although 
Scorpion/ARMS method is highly sensitive, it could detect 
only 29 variants of EGFR mutations. Tumors with some 
rare mutations may still have response to EGFR-TKI.24,25 
It could partly explain why some patients whose tumors 
were EGFR-WT by Scorpion/ARMS method still achieved 
partial response in this study. Fourth, we did not per-
form Scorpion/ARMS assay in our positive control group 
(EGFR-mutant by DS method).
In conclusion, EGFR mutation testing by DS method 
may misdiagnose up to one-fifth of “EGFR-WT” lung adeno-
carcinoma patients in a high EGFR mutation prevalence area. 
This can have significant adverse impact on the treatment 
decision for both physicians and patients. It will also severely 
jeopardize the clinical outcomes of EGFR-mutant patients if 
they are excluded from the use of EGFR-TKI due to a false-
negative testing result. Our study suggested a similar EGFR-
TKI response and survival in patients with EGFR mutation 
no matter it was determined by DS or Scorpion/ARMS alone. 
Future prospective studies are warranted to recapitulate our 
current retrospective observation.
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TABLE 2.  Clinical Characteristics in Patients Who Had 
Received EGFR-TKI Treatment
Group A  
(n = 64)
Group B  
(n = 21)
Group C  
(n = 58)
Age
  Median (range) 64 (30–91) 68 (44–81) 66 (41–85)
Sex
  Male 41 12 24
  Female 23 9 34
Smoking history
  Never 31 17 47
  Ever 33 4 11
Stage
  IIIB 4 2 5
  IV 60 19 53
Number of treatment before EGFR-TKI
  0 34 9 31
  1 23 10 23
  ≥2 7 2 4
EGFR mutation status
  Wild-type 64 0 0
  Exon 19 deletion 0 9 31
  L858R 0 10 24
  Exon 19 deletion and 
L858R
0 1 3
  L861Q 0 1 0
Tumor response evaluation
  Measurable 41 19 55
  Nonmeasurable 23 2 3
EGFR-TKI treatment
  Gefitinib 20 8 32
  Erlotinib 44 13 26
Tumor response
  Partial response 4 14 38
  Stable disease 8 4 11
  Progressive disease 29 1 6
  Not evaluable 23 2 3
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
Group A consists of 64 patients who had EGFR-WT tumors defined by both 
mutation detection methods, Group B consists of  21 patients who had tumors with 
EGFR mutations which were detected by Scorpion/ARMS but not DS method. Group 
C is a positive control group consisting of 58 lung adenocarcinoma patients who 
had sensitive EGFR mutations detected by DS method and had been treated with 
EGFR-TKI. 
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FIGURE 2.  Progression-free survival 
(A) and overall survival (B) in patients 
stratified according to the EGFR 
mutation status and EGFR mutation 
testing methods. (Thin line, DS: WT 
and Scorpion/ARMS: WT; Thick line, 
DS: WT and Scorpion/ARMS: mutant; 
Dash line, DS: mutant and Scorpion/
ARMS: not done). WT, wild-type; 
EGFR, epidermal growth factor recep-
tor; DS, direct sequencing; ARMS, 
Amplification Refractory Mutation 
System.
